Respiratory News and Research

RSS

Chloride-restrictive intravenous fluids reduce risk for kidney injury

The restrictive use of chloride in intravenous fluids reduces the risk for acute kidney injury and renal replacement therapy, research shows.

18 Oct 2012

Soccer scores hat-trick for hypertensive men

Soccer training can significantly reduce blood pressure and improve aerobic fitness in hypertensive middle-aged men, researchers say.

17 Oct 2012

Intermediate-acting neuromuscular block use ‘needs revisiting’

The use of intermediate-acting neuromuscular blocking agents during general anesthesia may increase the risk for clinically meaningful respiratory complications, researchers report in the BMJ.

17 Oct 2012

Philips to showcase advancements that allow patients to sleep and breathe easier at Medtrade 2012

Philips Respironics, a unit of Royal Philips Electronics, today at Medtrade 2012 showcases advancements that allow patients to sleep and breathe easier, demonstrating its commitment to improving the quality of life of those who suffer from chronic sleep and respiratory conditions.

17 Oct 2012

‘Gene for speed’ researcher awarded Ramaciotti Medal

Professor Kathryn North AM, the researcher responsible for discovering the ‘gene for speed’, has been awarded the prestigious Ramaciotti Medal for Excellence in Biomedical Research and a $50,000 grant.

16 Oct 2012

Early pollution exposure has long-lasting respiratory effects

Exposure to traffic-related pollution during the first year of life continues to affect lung function at age 8 years, show the results of a Swedish study.

16 Oct 2012

Experts blaze TRAIL for pulmonary arterial hypertension therapy

Researchers have shown that the cell signaling molecule tumor necrosis factor-related apoptosis-inducing ligand may be a potential therapeutic target for pulmonary arterial hypertension.

16 Oct 2012

U-M professor receives 2012 ASA Excellence in Research Award

The American Society of Anesthesiologists (ASA) today presented Ralph Lydic, Ph.D. with its 2012 ASA Excellence in Research Award. Dr. Lydic, well known for his research on the neurobiology of sleep and breathing, received the award at the ANESTHESIOLOGY 2012 annual meeting in Washington, D.C.

16 Oct 2012

USAID recognizes 5th annual Global Handwashing Day

USAID recognizes the fifth annual Global Handwashing Day on Monday, noting on its webpage that "studies show that washing hands with soap is one of the most effective and inexpensive ways to prevent diseases," with the ability to "cut deaths from diarrhea by almost half and from acute respiratory infections by a quarter."

16 Oct 2012

Direct link between fuel exposure and damage to genetic material

An experiment carried out on rodents exposed to fuel similar to that of the Prestige tanker oil spill - which took place nearly a decade ago - shows that inhalation of the fuel causes damage to genetic material. According to the study, led by the University of A Coru-a, the results could be used in relation to people who carry out the industrial cleaning of coasts.

16 Oct 2012

Cigarette smoke adversely affects the developing human airway

Research presented at the ANESTHESIOLOGY 2012 annual meeting revealed cigarette smoke adversely affects the developing human airway, especially in prematurity. Fetuses and premature babies exposed to cigarette smoke are at greater risk for developing childhood respiratory diseases, such as asthma.

16 Oct 2012

NIAID-funded study to evaluate PPSV23 and PCV13 in Phase Iib pneumococcal trial

Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases.

16 Oct 2012

Current status, challenges and opportunities of pulmonary vaccine delivery

In addition to the obvious benefit of eliminating the need for an injection, new vaccine delivery methods via the lungs offer particular advantages for protecting against infectious agents that enter the body through the respiratory track.

16 Oct 2012

Sterile acellular matrices 'reliable in expander-based breast reconstruction'

Sterile human acellular dermal matrix offers reliable matrix incorporation and a low complication rate for expander-based breast reconstruction, the results of a US study indicate, which also suggest that sterilization does not affect incorporation success.

15 Oct 2012

HIV agent offers HER2-positive breast cancer hope

A drug used to treat HIV infection may be a new treatment line for patients with an aggressive type of breast cancer, US researchers believe.

15 Oct 2012

Obesity does not affect VTE risk after knee surgery

Being morbidly obese does not increase the risk for developing venous thromboembolism after total knee arthroplasty surgery, report US researchers.

15 Oct 2012

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today that the Company will make its first public presentation at the Sixth Annual Parkinson's Disease Therapeutics Conference, sponsored by The Michael J. Fox Foundation for Parkinson's Research, to be held on October 24th in New York City.

15 Oct 2012

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Genzyme, a Sanofi company announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2012

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

Merck, known as MSD outside the United States and Canada, today announced results from a Phase II trial for odanacatib, an investigational cathepsin K (cat-K) inhibitor in development for the treatment of osteoporosis in post-menopausal women.

15 Oct 2012

FDA expands approved indication for Genentech’s ACTEMRA to treat active rheumatoid arthritis

Genentech, Inc., a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ACTEMRA (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

13 Oct 2012